Plasma and Tissue SAA1 Levels in Cancer Patients to Predict Hyperprogression of Immunotherapy

Clinical trial NCT06276088 · RECRUITING

Trial details

NCT number: NCT06276088
Sponsor: Nanfang Hospital, Southern Medical University
Status: RECRUITING
Study type: OBSERVATIONAL

Immunotherapy Hyperprogression Biomarker

Start date: 2024-02-18
Primary completion: 2025-12-31
Enrollment: 374

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.